Literature DB >> 18574158

Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients.

Athanassios Kyrgidis1, Konstantinos Vahtsevanos, Georgios Koloutsos, Charalampos Andreadis, Ioannis Boukovinas, Zisis Teleioudis, Anna Patrikidou, Stefanos Triaridis.   

Abstract

PURPOSE: Osteonecrosis of the jaws (ONJ) was initially described in 2001 in patients receiving intravenous bisphosphonate (BP) treatment. The objective of the present study was to determine whether routine dental procedures can be considered as possible risk factors for the development of ONJ in breast cancer patients receiving BP. PATIENTS AND METHODS: Twenty breast cancer patients who developed ONJ receiving BP treatment were included in group A, whereas group B consisted of 40 matched controls (breast cancer patients who did not progress to ONJ receiving BP treatment). Routine dental care, smoking habits, history of tooth extraction, use of dentures, and root canal therapy were recorded.
RESULTS: Our results indicate that history of tooth extraction during zoledronic acid treatment (adjusted odds ratio [OR] = 16.4; 95% CI, 3.4 to 79.6) and the use of dentures (adjusted OR = 4.9; 95% CI, 1.2 to 20.1) increase the risk of developing ONJ.
CONCLUSION: The outcome of the present study suggests early referral by oncologists for dental evaluation for every patient to be treated with BP. These results raise the current American Society of Clinical Oncology Level of Evidence linking certain dental procedures with ONJ from V to III. Further studies are needed to assess other possible risk factors and also to highlight the etiopathogenesis mechanism of ONJ.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18574158     DOI: 10.1200/JCO.2008.16.2768

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  56 in total

1.  Outcome of treatment and parameters influencing recurrence in patients with bisphosphonate-related osteonecrosis of the jaws.

Authors:  Thomas Mücke; Janett Koschinski; Herbert Deppe; Stefan Wagenpfeil; Christoph Pautke; David A Mitchell; Klaus-Dietrich Wolff; Frank Hölzle
Journal:  J Cancer Res Clin Oncol       Date:  2010-10-07       Impact factor: 4.553

2.  New evidence on bisphosphonate related osteonecrosis of the jaws suggests dental referral prior to commencement of treatment.

Authors:  A Kyrgidis; St Triaridis; K Vahtsevanos
Journal:  Hippokratia       Date:  2009-01       Impact factor: 0.471

3.  Osteonecrosis of the jaw in patients receiving oral bisphosphonates.

Authors:  Athanassios Kyrgidis; Konstantinos Vahtsevanos
Journal:  Osteoporos Int       Date:  2009-10-28       Impact factor: 4.507

4.  Methods and Biostatistics: a concise guide for peer reviewers.

Authors:  A Kyrgidis; S Triaridis
Journal:  Hippokratia       Date:  2010-12       Impact factor: 0.471

5.  Novel therapy to reverse the cellular effects of bisphosphonates on primary human oral fibroblasts.

Authors:  Matthew Cozin; Bradley M Pinker; Kimberley Solemani; Jeremy M Zuniga; Stephen C Dadaian; Serge Cremers; Regina Landesberg; Srikala Raghavan
Journal:  J Oral Maxillofac Surg       Date:  2011-07-31       Impact factor: 1.895

6.  Osteonecrosis of the maxilla related to long-standing methamphetamine abuse: a possible new aspect in the etiology of osteonecrosis of the jaw.

Authors:  Jan Rustemeyer; Alex Melenberg; Klaus Junker; Aynur Sari-Rieger
Journal:  Oral Maxillofac Surg       Date:  2014-04-22

Review 7.  Screening, diagnosis and treatment of osteoporosis: a brief review.

Authors:  Roberto Bernabei; Anna Maria Martone; Elena Ortolani; Francesco Landi; Emanuele Marzetti
Journal:  Clin Cases Miner Bone Metab       Date:  2014-09

8.  Primary wound closure after tooth extraction for prevention of medication-related osteonecrosis of the jaw in patients under denosumab.

Authors:  Akihiko Matsumoto; Masanori Sasaki; Rainer Schmelzeisen; Yukiko Oyama; Yoshihide Mori; Pit Jacob Voss
Journal:  Clin Oral Investig       Date:  2016-02-29       Impact factor: 3.573

Review 9.  Mitigating osteonecrosis of the jaw (ONJ) through preventive dental care and understanding of risk factors.

Authors:  Jason T Wan; Douglas M Sheeley; Martha J Somerman; Janice S Lee
Journal:  Bone Res       Date:  2020-03-11       Impact factor: 13.567

10.  Regular dental check-ups could be of benefit for patients receiving intravenous bisphosphonates. Regarding 'risks and benefits of bisphosphonates'.

Authors:  A Kyrgidis; S Triaridis
Journal:  Br J Cancer       Date:  2008-08-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.